BARCLAYS
Barclays has appointed Daniel Hanna as Global Head of Sustainable Finance for the Corporate and Investment Bank with the responsibility for creating a market-leading center of excellence for sustainable finance. He will be based in London and joins the Corporate and Investment Bank’s Management Committee.
“The center of excellence will bring together the power of our 'One Barclays' approach to deliver a fuller suite of products, solutions, and expertise to clients as they navigate the transition to a low-carbon economy,” said Paul Compton, Global Head of Corporate and Investment Bank and President, Barclays Bank Plc. “He will partner closely with the Sustainable Capital Markets, Sustainable and Impact Banking, and the Sustainable Product Group teams, as well as with Barclays’ Sustainability and ESG team to ensure connectivity with Barclays’ broader firm-wide efforts.”
“We are focused on the delivery of our climate strategy, including capturing new opportunities to deepen client relationships and create new growth for Barclays’ businesses,” said Sasha Wiggins, Barclays’ Group Head of Public Policy and Corporate Responsibility. “Whilst we are already using our expertise across our Corporate and Investment Bank to help clients manage this period of extraordinary change, Daniel’s appointment gives us a powerful focus to create a real point of difference with clients.”
Mr. Hanna joins Barclays from Standard Chartered, where he was most recently Global Head of Sustainable Finance.
“Barclays was one of the first banks to commit to net zero by 2050 and has a fantastic track record of innovation in green and sustainable finance,” said Mr. Hanna. “As the world deals with the impact of high energy prices and climate change, Barclays has a strong platform to help channel capital to the new technologies, and companies, that can help economies decarbonize and drive sustainable growth.”
The transition to a low carbon economy is today’s defining opportunity for innovation and growth - supporting clients in their efforts to decarbonise and adapt their business models is a strategic priority at Barclays. There is a significant opportunity for Barclays to play a leading role in helping to meet the demand for financing to support the energy transition, channelling investment into new green technologies and low-carbon infrastructure projects. Barclays has already facilitated £74bn of green financing, including landmark projects such as supporting the UK Government to issue their first green bond, which will finance projects such as offshore wind and schemes to decarbonise homes and buildings. To find out more about Barclays’ approach to climate change, please visit our website.
About Barclays
Barclays is a British universal bank. We are diversified by business, by different types of customer and client, and geography. Our businesses include consumer banking and payments operations around the world, as well as a top-tier, full service, global corporate and investment bank, all of which are supported by our service company which provides technology, operations and functional services across the Barclays Group. For further information about Barclays, please visit our website home.barclays.
About Barclays Corporate and Investment Bank
Barclays is a consumer and wholesale bank, supporting individuals and small businesses through our consumer banking services, and larger businesses and institutions through our corporate and investment banking services. Our Corporate and Investment Bank is comprised of the Investment Banking, International Corporate Banking, Global Markets and Research businesses; it provides money managers, financial institutions, governments, supranational organisations and corporate clients with services and advice for their funding, financing, strategic and risk management needs. For further information about Barclays Corporate and Investment Bank, please visit our website www.cib.barclays.
About Barclays Commitment to Address Climate Change
In March 2020, Barclays announced an ambition to be a net zero bank by 2050, becoming one of the first banks to do so. Barclays is working to achieve net zero operations, investing in the continued decarbonisation of our operations, and in the development of a net zero pathway for the emissions from our supply chain. Barclays is also committed to aligning its financing with the goals and timelines of the Paris Agreement and to providing the green and sustainable finance required to transform the economies it serves.
About Barclays’ Sustainable Capital Markets (SCM) Team
Barclays’ Sustainable Capital Markets (SCM) team offers a broad range of ESG capital market product types and delivers across multiple client segments to help clients finance their sustainability journeys and formalise their sustainability commitments.
About Barclays’ Sustainable and Impact Banking (SIB) Team
Barclays’ Sustainable and Impact Banking (SIB) team advises and raises capital for emerging growth companies that are addressing ESG issues, as well as for existing clients navigating their energy transitions.
About Barclays’ Sustainable Product Group (SPG) Team
Barclays’ Sustainable Product Group (SPG) team offers a set of green products based on Barclays Green Finance Framework, including Green Innovation Finance, Green Loans, Green Asset Finance, Green Trade Finance, Green Infrastructure and Project Finance, and Green Deposits.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220907005147/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom